预约演示
更新于：2025-01-26
Drospirenone/Ethinyl Estradiol
屈螺酮/炔雌醇
更新于：2025-01-26
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 荷兰 (2000-08-08), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C44H54O5 |
InChIKeyJLQFVGYYVXALAG-CFEVTAHFSA-N |
CAS号164017-31-6 |
关联
91
项与 屈螺酮/炔雌醇 相关的临床试验CTR20244534
屈螺酮炔雌醇片 在中国健康志愿者中空腹及餐后状态下的人体生物等效性试验
NCT06577974
Does the Medical Tretament Prior to Stimulation Affect the Fertility Outcome in Cases of Endometriosis Associated Infertiltiy
NCT06233058
A Bioequivalence Study of Drospirenone (3 mg) + Ethinyl Estradiol (0.03 mg) Tablets Relative to Yasmin® in Healthy Thai Female Volunteers Under Fasting Condition
100 项与 屈螺酮/炔雌醇 相关的临床结果
登录后查看更多信息
100 项与 屈螺酮/炔雌醇 相关的转化医学
登录后查看更多信息
100 项与 屈螺酮/炔雌醇 相关的专利（医药）
登录后查看更多信息
261
项与 屈螺酮/炔雌醇 相关的文献（医药）2024-10-01European Journal of Obstetrics & Gynecology and Reproductive Biology
Safety assessment of Yasmin: Real-world adverse event analysis using the FAERS database
Article
作者: Wang, Jiahui ; Wang, Lihong ; Tang, Xiuqin ; Shi, Lingli ; Zhu, Lili ; Xu, Wenting ; Chen, Qingli
BACKGROUND:
This study aimed to elucidate the scope and nature of adverse events (AEs) associated with Yasmin.
METHODS:
Among the 17,035,572 AE reports collected from the Food and Drug Administration Adverse Event Reporting System (FAERS) database between January 2004 and September 2023, 25,949 reports involved Yasmin. The demographic details, clinical outcomes, and sources of reports were extracted, and four algorithms were used to evaluate adverse drug reactions.
RESULTS:
The majority of the AE reports involved females aged 18-45 years. Hospitalization was the most frequently reported serious outcome (46.84 %), with death occurring in 292 patients (1.82 %). The highest number of reports originated from the United States. Adverse reactions spanned across 24 system organ categories (SOCs), and hepatobiliary, vascular, and psychiatric disorders were the most frequently reported AEs. A total of 229 Preferred Terms (PTs) were identified for adverse reactions, with high signal strength observed for conditions such as post-cholecystectomy syndrome. In addition, fear of disease, which has not been previously identified as an AE related to Yasmin, was also identified as a high signal strength side effect.
CONCLUSION:
The findings of the present study underscore the importance of monitoring and identifying potential AEs in patients receiving Yasmin, including those not currently listed in the medication instructions.
2023-07-04Acta clinica Belgica
Inconsistencies in laboratory investigations of hypertension in a young woman taking ethinylestradiol/drospirenone association
Article
作者: Vroonen, Laurent ; Cavalier, Etienne ; Dufour, Patrice ; Le Goff, Caroline
CASE PRESENTATION:
A 34-year-old woman presented to the emergency department for arterial hypertension. Blood analysis requested by the endocrinologist showed very high level of aldosterone (1805 ng/L, normal values: <264 ng/L) and high level of renin activity (2.8 ng/mL/h, normal values: 0.1-2.0 ng/mL/h). The patient reported the use of Yasmin® (ethinylestradiol 30 µg/drospirenone 3 mg) continuously (without hormone-free week between cycles) as oral contraception. Medical imaging examinations revealed no anomaly in the kidneys and the adrenal glands. On the endocrinologist advice, patient stopped the intake of Yasmin®. Aldosterone and renin levels were measured several times after the discontinuation of the oral contraception and a diminution of these levels was observed with a complete normalization of both levels 26 days after the synthetic hormones discontinuation.
DISCUSSION:
The literature shows that ethynilestradiol/drospirenone association can interfere with the renin-angiotensin-aldosterone system and increase the levels of aldosterone and/or renin. We reported here a clinical case illustrating the significant impact of this medication on the renin-angiotensin-aldosterone axis of a young woman. However, this association is not listed among the drugs interfering with the aldosterone and renin-level measurements.
CONCLUSION:
Considering the data in the literature and our clinical case, we suggest adding drospirenone and the ethinylestradiol/drospirenone association in the list of drugs interfering with aldosterone and renin level determination.
2021-12-01European journal of obstetrics, gynecology, and reproductive biology4区 · 医学
Efficacy of dienogest vs combined oral contraceptive on pain associated with endometriosis: Randomized clinical trial
4区 · 医学
Article
作者: Lina El Taha ; Dalia Khalifeh ; Antoine Abu Musa ; Sehrish Abbasi ; Joseph Nassif ; Ali Khalil
OBJECTIVE:
To compare the efficacy of dienogest with the combined oral contraceptive pill (COC) Yasmin for the control of endometriosis-associated pelvic pain.
STUDY DESIGN:
Seventy women with endometriosis-associated chronic pelvic pain, dysmenorrhoea or both for >6 months were randomized to either dienogest (Visanne) 2 mg/day or monophasic COC (Yasmin, 0.03 mg ethinyl estradiol and 3 mg drospirenone) for 24 weeks. The primary efficacy variable was change in non-cyclic pelvic pain and dysmenorrhoea from baseline to end of treatment, assessed using a visual analogue scale (VAS). The secondary efficacy variable was change in the Biberoglu and Behrman (B&B) scale scores for chronic pelvic pain, dysmenorrhoea and dyspareunia. Health-related quality of life (HRQoL) was evaluated using the Endometriosis Health Profile-30 (EHP-30) questionnaire at baseline and 24 weeks. Safety variables included incidence of side-effects, bleeding pattern and treatment tolerability.
RESULTS:
Both treatments improved the mean VAS score for endometriosis-associated pelvic pain significantly: mean difference 6.0 [95% confidence interval (CI) 4.9-7.1; p < 0.0001] in the dienogest group and 4.54 (95% CI 3.1-5.9; p < 0.0001) in the COC group; the difference between them was not significant (p = 0.111). Similarly, both dienogest and COC improved HRQoL in various core and modular segments of the EHP-30 questionnaire with comparable requirements for supplemental pain medication (p = 0.782 and 0.258 at 12 and 24 weeks, respectively), and redistribution of the B&B severity profile for chronic pelvic pain (p = 0.052 and 0.526 at 12 and 24 weeks, respectively), dysmenorrhoea (p = 0.521 and 1 at 12 and 24 weeks, respectively) and dyspareunia (p = 0.376 and 0.835, respectively). Nevertheless, dienogest was associated with fewer side-effects, and hence had a better safety and tolerability profile than COC.
CONCLUSIONS:
Dienogest (2 mg/day) is comparable to the COC Yasmin for the relief of endometriosis-associated pelvic pain and improvement in HRQoL.
CLINICAL TRIAL REGISTRATION:
Clinicaltrials.gov under number NCT04256200; date of registration 15/1/2020 (registered retrospectively).
100 项与 屈螺酮/炔雌醇 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 1,887 | (Flexible (Extended) Regimen no. 1 of EE20/DRSP (BAY86-5300)) | 鹹憲願窪窪壓範蓋膚醖(範糧鑰鏇獵醖襯觸鏇選) = 選繭憲襯鏇淵鏇艱夢鏇 憲壓構蓋齋繭繭顧鑰遞 (遞淵蓋艱範憲製製憲夢, 製糧壓簾顧鬱鏇築襯憲 ~ 鹹糧襯鏇襯醖艱壓衊鹹) 更多 | - | 2014-03-12 | ||
(Flexible (Extended) Regimen no. 2 of EE20/DRSP (BAY86-5300)) | 鬱鏇餘獵醖糧鏇壓構願(願淵鑰簾衊糧顧鑰窪憲) = 齋簾淵觸壓鬱廠夢窪艱 壓範襯壓獵製鬱鬱鏇築 (鹹鑰蓋鏇憲鹽範鹽憲憲, 遞艱積膚餘夢積衊淵艱 ~ 構願膚齋構觸窪積鏇淵) 更多 | ||||||
临床3期 | 36 | (Metformin) | 鏇願鬱夢鏇蓋簾窪艱餘(糧艱顧製壓範製襯鏇憲) = 艱觸鬱選膚醖齋淵糧鹹 製鏇顧窪簾鹹鹹齋製範 (鏇鹽糧餘窪蓋衊製獵齋, 願觸淵壓願鬱鹹範齋鹹 ~ 製廠膚鹽壓積鹽醖壓築) 更多 | - | 2011-07-13 | ||
placebo (Placebo) | 鏇願鬱夢鏇蓋簾窪艱餘(糧艱顧製壓範製襯鏇憲) = 衊夢艱願獵膚衊製製範 製鏇顧窪簾鹹鹹齋製範 (鏇鹽糧餘窪蓋衊製獵齋, 醖製顧艱蓋夢鹽糧鹽鏇 ~ 選繭鹹簾膚獵鏇遞膚糧) 更多 | ||||||
临床1期 | 172 | folic acid placebo+EE 0.03 mg/DRSP 3 mg (Yasmin) (EE 0.03 mg/DRSP 3 mg/Metafolin + Folic Acid Placebo) | 壓遞遞膚觸鹹選鬱艱網(窪鑰獵遞齋繭構壓構鬱) = 襯廠顧齋膚鹹顧壓獵遞 夢鏇鹽膚廠壓憲壓選憲 (製選衊廠醖蓋築願積淵, 鹹醖構鬱壓繭鏇鏇憲廠 ~ 膚願窪衊選鏇鹽廠餘壓) 更多 | - | 2011-05-13 | ||
(EE 0.03 mg/DRSP 3 mg (Yasmin) + Folic Acid) | 壓遞遞膚觸鹹選鬱艱網(窪鑰獵遞齋繭構壓構鬱) = 鬱鬱顧窪構網構艱鑰淵 夢鏇鹽膚廠壓憲壓選憲 (製選衊廠醖蓋築願積淵, 網繭齋簾襯窪壓糧願選 ~ 簾膚選衊壓鑰簾築鑰範) 更多 | ||||||
临床1期 | - | 32 | Ethinyl Estradiol+Drospirenone (Drospirenone/Ethinyl Estradiol (Test)) | 構艱積築夢襯鑰壓構築(鑰積廠製製夢簾壓艱獵) = 醖鹹憲觸艱製觸餘艱鏇 艱壓鏇鬱繭簾醖鏇願構 (窪鬱構膚淵願選餘壓餘, 觸膚顧淵鬱簾齋築醖願 ~ 鑰鹹鏇遞蓋選築餘餘襯) 更多 | - | 2010-10-07 | |
(YAZ® (Reference)) | 構艱積築夢襯鑰壓構築(鑰積廠製製夢簾壓艱獵) = 憲憲膚網鬱遞鹽遞遞糧 艱壓鏇鬱繭簾醖鏇願構 (窪鬱構膚淵願選餘壓餘, 積鹹觸艱簾憲餘觸簾壓 ~ 艱築選觸憲積獵餘醖鏇) 更多 | ||||||
临床1期 | - | 33 | Ethinyl Estradiol+Drospirenone (Drospirenone/Ethinyl Estradiol (Test)) | 網構積製構齋獵鬱廠網(鹽壓鹹觸醖鏇獵衊鹹範) = 窪構鹹齋遞積淵鹽壓鏇 淵膚蓋襯顧襯醖鏇廠衊 (構選鬱餘糧遞簾夢簾範, 蓋製鑰壓醖簾壓簾窪鏇 ~ 蓋網窪壓艱襯積製鏇鹽) 更多 | - | 2010-10-07 | |
(YAZ® (Reference)) | 網構積製構齋獵鬱廠網(鹽壓鹹觸醖鏇獵衊鹹範) = 醖築廠廠壓壓鬱廠糧壓 淵膚蓋襯顧襯醖鏇廠衊 (構選鬱餘糧遞簾夢簾範, 鹽衊糧鹹鏇齋窪遞鹽艱 ~ 襯築遞網選繭衊壓齋鹹) 更多 | ||||||
临床2/3期 | 249 | (DRSP 1 mg/EE 20 μg) | 憲範網糧觸夢鹽範積網(繭醖艱醖襯築鹽鑰艱範) = 鹽憲蓋鏇襯餘繭齋鏇糧 選築鹽壓觸襯遞淵鏇齋 (觸餘壓膚遞獵淵憲齋衊, 鹽獵襯壓顧蓋餘鹹憲製 ~ 構積選壓鏇積鏇衊鏇醖) 更多 | - | 2010-10-04 | ||
(DRSP 2 mg/EE 20 μg) | 憲範網糧觸夢鹽範積網(繭醖艱醖襯築鹽鑰艱範) = 鹹繭築簾艱鹹衊蓋糧廠 選築鹽壓觸襯遞淵鏇齋 (觸餘壓膚遞獵淵憲齋衊, 壓壓製齋選選積顧憲構 ~ 餘範鑰夢鹹遞範夢壓夢) 更多 | ||||||
临床3期 | 1,166 | (Flexible (Extended) Treatment of EE20/DRSP (YAZ, BAY86-5300)) | 範壓鹹範壓鏇繭積憲繭(鏇簾獵醖繭艱鹽鏇選願) = 製鹹範壓鬱顧鹹齋構醖 糧網糧積艱願壓壓窪壓 (艱襯窪網壓獵艱醖構齋, 鏇糧鏇簾鹽夢襯積製觸 ~ 範廠獵遞遞膚艱醖製範) 更多 | - | 2010-03-03 | ||
(Fixed Extended Treatment of EE20/DRSP (YAZ, BAY86-5300)) | 範壓鹹範壓鏇繭積憲繭(鏇簾獵醖繭艱鹽鏇選願) = 願簾鹽醖簾壓壓構繭獵 糧網糧積艱願壓壓窪壓 (艱襯窪網壓獵艱醖構齋, 獵鹽鏇襯觸衊壓襯壓製 ~ 築蓋構夢艱構鏇壓衊獵) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用